Davide Massimi

A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach

Brigida Barberio, Sonia Facchin, Ilaria Patuzzi et al. · Gut Microbes · 2022 · 82 citations · Full text

Life Sciences, Immunology, Microbiology +17

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

Linda Cingolani, Brigida Barberio, Fabiana Zingone et al. · Scientific Reports · 2021 · 37 citations · Full text

Medicine, Immunology, Pharmacotherapy +15

Prophylactic underwater vessel coagulation for submucosal endoscopy

Antonio Capogreco, Cesare Hassan, Federico De Blasio et al. · Gut · 2024 · 24 citations

Medicine, Surgery, Hemostasis +5

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study

Brigida Barberio, Fabiana Zingone, R. D’Incà et al. · Clinical and Translational Gastroenterology · 2020 · 22 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

Brigida Barberio, Linda Cingolani, Cristina Canova et al. · Therapeutic Advances in Gastroenterology · 2021 · 20 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14